Evidence map›Paper›PMID 27303683›Full record

ArticlemSphere

Viral Determinants of miR-122-Independent Hepatitis C Virus Replication.

Sharon E Hopcraft, Kristopher D Azarm, Benjamin Israelow, Nicolas Lévêque, Megan C Schwarz, Tien-Huei Hsu, Matthew T Chambers, Marion Sourisseau, Bert L Semler, Matthew J Evans

Open access · goldAbstract read
In one paragraph

Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. miR-122-based therapies select for three distinct resistance mechanisms based on alterations in RNA structure.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Impact of CRISPR-Cas System on Antiviral Therapy.Advanced pharmaceutical bulletin · 2018
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sharon E HopcraftDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kristopher D AzarmDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Benjamin IsraelowDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nicolas LévêqueClinical and Molecular Virology Unit (EA-4684 CardioVir), School of Medicine, University of Reims Champagne-Ardenne, Reims, France; Department of Microbiology and Molecular Genetics, School of Medicine, University of California Irvine, California, USA.
Megan C SchwarzDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tien-Huei HsuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Matthew T ChambersDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Marion SourisseauDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Bert L SemlerDepartment of Microbiology and Molecular Genetics, School of Medicine, University of California Irvine, California, USA.
Matthew J EvansDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Icahn School of Medicine at Mount Sinai · USUniversité de Reims Champagne-Ardenne · FRUniversity of California, Irvine · US

Funding

TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5M
POLIOVIRUS GENE FUNCTION AND REGULATIONR01AI022693 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEMLER, BERT L · 1985 to 2015
$4.6M
Hepatitis C virus polarized cell entry pathwaysR01DK095125 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EVANS, MATTHEW J · 2012 to 2016
$1.8M
NIAID NIH HHS R01 AI022693NIAID NIH HHS T32 AI007647NIDDK NIH HHS R01 DK095125
6 · The paper itself

Abstract

Hepatitis C virus (HCV) replication requires binding of the liver-specific microRNA (miRNA) miR-122 to two sites in the HCV 5' untranslated region (UTR). Although we and others have shown that viral genetics impact the amount of active miR-122 required for replication, it is unclear if HCV can replicate in the complete absence of this miRNA. To probe the absolute requirements for miR-122 and the genetic basis for those requirements, we used clustered regularly interspaced short palindromic repeat (CRISPR) technology to knock out miR-122 in Huh-7.5 cells and reconstituted these knockout (KO) cells with either wild-type miR-122 or a mutated version of this miRNA. We then characterized the replication of the wild-type virus, as well as a mutated HCV bearing 5' UTR substitutions to restore binding to the mutated miR-122, in miR-122 KO Huh-7.5 cells expressing no, wild-type, or mutated miR-122. We found that while replication was most efficient when wild-type or mutated HCV was provided with the matched miR-122, inefficient replication could be observed in cells expressing the mismatched miR-122 or no miR-122. We then selected viruses capable of replicating in cells expressing noncognate miR-122 RNAs. Unexpectedly, these viruses contained multiple mutations throughout their first 42 nucleotides that would not be predicted to enhance binding of the provided miR-122. These mutations increased HCV RNA replication in cells expressing either the mismatched miR-122 or no miR-122. These data provide new evidence that HCV replication can occur independently of miR-122 and provide unexpected insights into how HCV genetics influence miR-122 requirements. IMPORTANCE Hepatitis C virus (HCV) is the leading cause of liver cancer in the Western Hemisphere. HCV infection requires miR-122, which is expressed only in liver cells, and thus is one reason that replication of this virus occurs efficiently only in cells of hepatic origin. To understand how HCV genetics impact miR-122 usage, we knocked out miR-122 using clustered regularly interspaced short palindromic repeat (CRISPR) technology and adapted virus to replicate in the presence of noncognate miR-122 RNAs. In doing so, we identified viral mutations that allow replication in the complete absence of miR-122. This work provides new insights into how HCV genetics influence miR-122 requirements and proves that replication can occur without this miRNA, which has broad implications for how HCV tropism is maintained.

Indexed as

CRISPRhepatitis C virusmicroRNAmiR-122

Identifiers

PMID27303683
PMCPMC4863629
OpenAlexW2324247498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.